Advanced Research on Radioresistant Tumors
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 July 2025 | Viewed by 193
Special Issue Editors
Interests: radiation biology; cancer; radiation oncology; apoptosis; immunotherapy
Interests: radiotherapy; radiation oncology
Special Issue Information
Dear Colleagues,
Radioresistant tumors pose a critical challenge in oncology, often resulting in poor patient outcomes despite ongoing advancements in therapeutic modalities. The aim of this Special Issue, titled "Advanced Research on Radioresistant Tumors", is to provide a comprehensive platform for understanding and overcoming radioresistance, with a focus on the latest advancements in radiotherapy, immunotherapy, chemotherapy, and genetic research.
By covering cutting-edge developments in radiotherapy techniques such as proton and heavy ion therapy, exploring novel genetic findings, and discussing the integration of immunomodulatory strategies, this Issue will offer valuable insights into overcoming treatment barriers and enhancing therapeutic efficacy.
Our objective is to collect a diverse range of articles that not only drive innovation but also serve as a practical guide for clinicians and experts in the field. We aim to create a resource that clinicians can utilize in clinical settings, showcasing the latest findings in specific cancers, highlighting the latest treatment possibilities, and presenting novel ideas for tackling radioresistance. This Special Issue aspires to bridge the gap between research and clinical application, enabling better decision making and improved patient outcomes in the management of radioresistant tumors.
Scope: This Special Issue invites original research articles, reviews, and clinical studies that focus on the following areas:
1. Genetics and Molecular Mechanisms:
New insights into the genetic and molecular pathways driving radioresistance, including novel gene mutations, epigenetic changes, and biomarkers for predicting treatment response.
2. Radiotherapy Innovations:
Emerging techniques, such as proton therapy, heavy ion therapy, and adaptive radiotherapy, aimed at overcoming hypoxia and improving local control in resistant tumors.
3. Immunotherapy Strategies:
Integrating radiotherapy with immunotherapy approaches, such as immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapy, to boost anti-tumor immune responses.
4. Chemotherapy and Combination Treatments:
Investigations into the synergistic effects of combining radiotherapy with chemotherapy, targeted therapies, or molecular inhibitors to sensitize tumors to radiation.
5. Personalized Approaches:
Utilizing advanced imaging and genetic profiling to adapt radiotherapy and multimodal treatments to the unique characteristics of individual tumors.
Dr. Mansoor M. Ahmed
Dr. Kamila Rawojć
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radioresistant tumors
- radiotherapy innovations
- proton and heavy ion therapy
- immunotherapy and radiotherapy combinations
- genetic biomarkers
- tumor hypoxia
- combination treatment strategies
- molecular oncology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
